Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis.

Cocco E.

J Neurol Neurosurg Psychiatry. 2019 Jul 17. pii: jnnp-2019-321121. doi: 10.1136/jnnp-2019-321121. [Epub ahead of print] No abstract available.

PMID:
31315907
2.

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group.

J Neurol. 2019 Jun 17. doi: 10.1007/s00415-019-09424-8. [Epub ahead of print]

PMID:
31209573
3.

"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.

Calabrese M, Gasperini C, Tortorella C, Schiavi G, Frisullo G, Ragonese P, Fantozzi R, Prosperini L, Annovazzi P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Malucchi S, Lo Fermo S, De Luca G, Stromillo ML, Cocco E, Gallo A, Paolicelli D, Lanzillo R, Tomassini V, Pesci I, Rodegher ME, Solaro C; RIREMS group (Rising Italian Researchers in Multiple Sclerosis).

Neurology. 2019 May 28;92(22):e2527-e2537. doi: 10.1212/WNL.0000000000007573. Epub 2019 May 1.

PMID:
31043476
4.

Prevalence and role of HER2 mutations in cancer.

Cocco E, Lopez S, Santin AD, Scaltriti M.

Pharmacol Ther. 2019 Jul;199:188-196. doi: 10.1016/j.pharmthera.2019.03.010. Epub 2019 Apr 2. Review.

PMID:
30951733
5.

PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.

Toska E, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku M, Xu G, Park J, Minuesa G, Shifman SG, Socci ND, Koche R, Leslie CS, Scaltriti M, Baselga J.

Cell Rep. 2019 Apr 2;27(1):294-306.e5. doi: 10.1016/j.celrep.2019.02.111.

6.

Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E.

J Neurol. 2019 Jun;266(6):1405-1411. doi: 10.1007/s00415-019-09272-6. Epub 2019 Mar 12.

PMID:
30863891
7.

Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy.

Lorefice L, Murgia F, Fenu G, Frau J, Coghe G, Murru MR, Tranquilli S, Visconti A, Marrosu MG, Atzori L, Cocco E.

Neurotherapeutics. 2019 Feb 28. doi: 10.1007/s13311-019-00721-8. [Epub ahead of print]

PMID:
30820880
8.

Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs.

Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM.

Front Oncol. 2019 Jan 22;9:9. doi: 10.3389/fonc.2019.00009. eCollection 2019.

9.

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.

J Neurol. 2019 Mar;266(3):707-716. doi: 10.1007/s00415-019-09193-4. Epub 2019 Jan 16.

PMID:
30649617
10.

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.

Cocco E, Benhamida J, Middha S, Zehir A, Mullaney K, Shia J, Yaeger R, Zhang L, Wong D, Villafania L, Nafa K, Scaltriti M, Drilon A, Saltz L, Schram AM, Stadler ZK, Hyman DM, Benayed R, Ladanyi M, Hechtman JF.

Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.

PMID:
30643016
11.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7.

PMID:
30630630
12.

Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers.

Fenu G, Fronza M, Lorefice L, Arru M, Coghe G, Frau J, Marrosu MG, Cocco E.

BMC Neurol. 2018 Dec 19;18(1):212. doi: 10.1186/s12883-018-1224-z.

13.

Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study.

Lorefice L, Frau J, Coghe G, Pitzalis R, Gessa I, Contu F, Barracciu MA, Marrosu MG, Cocco E, Fenu G.

Mult Scler Relat Disord. 2019 Jan;27:74-78. doi: 10.1016/j.msard.2018.10.011. Epub 2018 Oct 16.

PMID:
30343253
14.

Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score.

Coghe G, Pau M, Mamusa E, Pisano C, Corona F, Pilloni G, Porta M, Marrosu G, Vannelli A, Frau J, Lorefice L, Fenu G, Marrosu MG, Cocco E.

Disabil Rehabil. 2018 Oct 18:1-6. doi: 10.1080/09638288.2018.1506946. [Epub ahead of print]

PMID:
30334469
15.

NTRK fusion-positive cancers and TRK inhibitor therapy.

Cocco E, Scaltriti M, Drilon A.

Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Review.

PMID:
30333516
16.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
17.

Association between brain atrophy and cognitive motor interference in multiple sclerosis.

Coghe G, Fenu G, Lorefice L, Zucca E, Porta M, Pilloni G, Corona F, Frau J, Giovanna Marrosu M, Pau M, Cocco E.

Mult Scler Relat Disord. 2018 Oct;25:208-211. doi: 10.1016/j.msard.2018.07.045. Epub 2018 Jul 31.

PMID:
30103173
18.

Top-down proteomic profiling of human saliva in multiple sclerosis patients.

Manconi B, Liori B, Cabras T, Vincenzoni F, Iavarone F, Lorefice L, Cocco E, Castagnola M, Messana I, Olianas A.

J Proteomics. 2018 Sep 15;187:212-222. doi: 10.1016/j.jprot.2018.07.019. Epub 2018 Aug 4.

PMID:
30086402
19.

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; ; On behalf of the iMUST Group.

Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390. [Epub ahead of print]

PMID:
30044207
20.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.

PMID:
29941483
21.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.

22.

Clinical activity after fingolimod cessation: disease reactivation or rebound?

Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P, Signoriello E, Maniscalco GT, La Gioia S, Cordioli C, Frigeni B, Rasia S, Fenu G, Grasso R, Sartori A, Lanzillo R, Stromillo ML, Rossi S, Forci B, Cocco E; i-MuST study group.

Eur J Neurol. 2018 Oct;25(10):1270-1275. doi: 10.1111/ene.13694. Epub 2018 Jul 10.

PMID:
29851435
23.

Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study.

Fenu G, Arru M, Lorefice L, Frau J, Coghe G, Fronza M, Loi L, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Jul;23:83-87. doi: 10.1016/j.msard.2018.05.012. Epub 2018 May 16.

PMID:
29800885
24.

A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls.

Frau J, Fenu G, Signori A, Coghe G, Lorefice L, Barracciu MA, Sechi V, Cabras F, Badas M, Marrosu MG, Cocco E.

BMC Neurol. 2018 May 11;18(1):67. doi: 10.1186/s12883-018-1065-9.

25.

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab.

Frau J, Coghe G, Lorefice L, Fenu G, Cocco E.

Neuropsychiatr Dis Treat. 2018 Apr 23;14:1093-1099. doi: 10.2147/NDT.S147874. eCollection 2018. Review.

26.

KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2.

Cocco E, Leo M, Canzonetta C, Di Vito S, Mai A, Rotili D, Di Napoli A, Vecchione A, De Nunzio C, Filetici P, Stoppacciaro A.

Clin Epigenetics. 2018 Apr 4;10:44. doi: 10.1186/s13148-018-0473-4. eCollection 2018.

27.

Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment.

Frau J, Coghe G, Casanova P, Sardu C, Lorefice L, Fenu G, Marrosu MG, Cocco E.

Eur J Neurol. 2018 Aug;25(8):1063-1068. doi: 10.1111/ene.13650. Epub 2018 Apr 25.

PMID:
29611885
28.

Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.

Coghe G, Corona F, Marongiu E, Fenu G, Frau J, Lorefice L, Crisafulli A, Galli M, Concu A, Marrosu MG, Pau M, Cocco E.

J Neurol. 2018 Jun;265(6):1328-1333. doi: 10.1007/s00415-018-8836-5. Epub 2018 Mar 24.

PMID:
29574556
29.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
30.

Adult brain volume in multiple sclerosis: The impact of paediatric onset.

Fenu G, Lorefice L, Loi L, Sechi V, Contu F, Coghe G, Frau J, Spinicci G, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Apr;21:103-107. doi: 10.1016/j.msard.2018.03.004. Epub 2018 Mar 6.

PMID:
29544192
31.

Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.

Lorefice L, Fenu G, Pitzalis R, Scalas G, Frau J, Coghe G, Musu L, Sechi V, Barracciu MA, Marrosu MG, Cocco E.

J Neurol. 2018 May;265(5):1096-1101. doi: 10.1007/s00415-018-8811-1. Epub 2018 Mar 5.

PMID:
29508133
32.

Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test.

Coghe G, Pilloni G, Zucca E, Porta M, Corona F, Frau J, Fenu G, Lorefice L, Marrosu MG, Pau M, Cocco E.

Mult Scler Relat Disord. 2018 May;22:8-11. doi: 10.1016/j.msard.2018.02.026. Epub 2018 Feb 24.

PMID:
29501850
33.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
34.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
35.

Cognition in multiple sclerosis: Between cognitive reserve and brain volume.

Fenu G, Lorefice L, Arru M, Sechi V, Loi L, Contu F, Cabras F, Coghe G, Frau J, Fronza M, Sbrescia G, Lai V, Boi M, Mallus S, Murru S, Porcu A, Barracciu MA, Marrosu MG, Cocco E.

J Neurol Sci. 2018 Mar 15;386:19-22. doi: 10.1016/j.jns.2018.01.011. Epub 2018 Jan 10.

PMID:
29406960
36.

The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis.

Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E.

Work. 2018;60(2):263-270. doi: 10.3233/WOR-182682.

PMID:
29400690
37.

Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study.

Lorefice L, Fenu G, Fois M, Frau J, Coghe G, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Feb;20:104-108. doi: 10.1016/j.msard.2018.01.012. Epub 2018 Jan 31.

PMID:
29360061
38.

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D, Coghe G, Lorefice L, Fenu G, Bedin R, Sola P, Marrosu MG, Cocco E.

J Neurol. 2018 Feb;265(2):424-430. doi: 10.1007/s00415-017-8716-4. Epub 2017 Dec 22.

PMID:
29273846
39.

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

Frau J, Carai M, Coghe G, Fenu G, Lorefice L, La Nasa G, Mamusa E, Vacca A, Marrosu MG, Cocco E.

J Neurol. 2018 Feb;265(2):410-416. doi: 10.1007/s00415-017-8718-2. Epub 2017 Dec 21.

PMID:
29270686
40.

Texting while walking differently alters gait patterns in people with multiple sclerosis and healthy individuals.

Pau M, Corona F, Pilloni G, Porta M, Coghe G, Cocco E.

Mult Scler Relat Disord. 2018 Jan;19:129-133. doi: 10.1016/j.msard.2017.11.021. Epub 2017 Dec 2.

PMID:
29216541
41.

PML in a person with multiple sclerosis: Is teriflunomide the felon?

Lorefice L, Fenu G, Gerevini S, Frau J, Coghe G, Barracciu MA, Contu F, Marrosu MG, Cocco E.

Neurology. 2018 Jan 9;90(2):83-85. doi: 10.1212/WNL.0000000000004804. Epub 2017 Dec 6. No abstract available.

PMID:
29212829
42.

Validation of the Arm Profile Score in assessing upper limb functional impairments in people with multiple sclerosis.

Corona F, Gervasoni E, Coghe G, Cocco E, Ferrarin M, Pau M, Cattaneo D.

Clin Biomech (Bristol, Avon). 2018 Jan;51:45-50. doi: 10.1016/j.clinbiomech.2017.11.010. Epub 2017 Nov 22.

PMID:
29179033
43.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M.

J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

44.

Do gait patterns differ in men and women with multiple sclerosis?

Pau M, Corona F, Pilloni G, Porta M, Coghe G, Cocco E.

Mult Scler Relat Disord. 2017 Nov;18:202-208. doi: 10.1016/j.msard.2017.10.005. Epub 2017 Oct 9.

PMID:
29141811
45.

Brain volume in early MS patients with and without IgG oligoclonal bands in CSF.

Fenu G, Lorefice L, Sechi V, Loi L, Contu F, Cabras F, Coghe G, Frau J, Secci MA, Melis C, Schirru L, Costa G, Melas V, Arru M, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler Relat Disord. 2018 Jan;19:55-58. doi: 10.1016/j.msard.2017.11.005. Epub 2017 Nov 8.

PMID:
29132035
46.

Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.

Lorefice L, Fenu G, Sardu C, Frau J, Coghe G, Costa G, Schirru L, Secci MA, Sechi V, Barracciu MA, Marrosu MG, Cocco E.

Mult Scler. 2019 Jan;25(1):23-30. doi: 10.1177/1352458517739989. Epub 2017 Nov 7.

PMID:
29111883
47.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
48.

Cerebrospinal fluid analysis and the determination of oligoclonal bands.

Gastaldi M, Zardini E, Leante R, Ruggieri M, Costa G, Cocco E, De Luca G, Cataldo I, Biagioli T, Ballerini C, Castellazzi M, Fainardi E, Pettini P, Zaffaroni M, Giunti D, Capello E, Bernardi G, Ciusani E, Giannotta C, Nobile-Orazio E, Bazzigaluppi E, Passerini G, Bedin R, Sola P, Brivio R, Cavaletti G, Sala A, Bertolotto A, Desina G, Leone MA, Mariotto S, Ferrari S, Paternoster A, Giavarina D, Lolli F, Franciotta D.

Neurol Sci. 2017 Oct;38(Suppl 2):217-224. doi: 10.1007/s10072-017-3034-2. Review.

PMID:
29030765
49.

Differential Lipid Composition and Gene Expression in the Semi-Russeted "Cox Orange Pippin" Apple Variety.

Legay S, Cocco E, André CM, Guignard C, Hausman JF, Guerriero G.

Front Plant Sci. 2017 Sep 26;8:1656. doi: 10.3389/fpls.2017.01656. eCollection 2017.

50.

Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.

Frau J, Coghe G, Fenu G, Lorefice L, Cocco E.

Neurol Sci. 2018 Feb;39(2):389-390. doi: 10.1007/s10072-017-3135-y. Epub 2017 Oct 7. No abstract available.

PMID:
28986705

Supplemental Content

Support Center